Hydroxamic acid hybrids as the potential anticancer agents: An Overview.
Anticancer
Drug resistance
Hybrid compounds
Hydroxamic acid
Mechanism of action
Structure-activity relationship
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
01 Nov 2020
01 Nov 2020
Historique:
received:
08
06
2020
revised:
12
07
2020
accepted:
20
07
2020
pubmed:
14
8
2020
medline:
20
4
2021
entrez:
14
8
2020
Statut:
ppublish
Résumé
Hydroxamic acid derivatives are potential histone deacetylase inhibitors, and several hydroxamic acid-based histone deacetylase inhibitors have already been used clinically as potent anticancer agents, so hydroxamic acid derivatives are useful scaffolds for the development of novel anticancer agents. Hybridization of hydroxamic acid moiety with other anticancer pharmacophores can overcome drug resistance and improve the specificity, so rational design of hydroxamic acid hybrids may provide valuable therapeutic interventions for the treatment of cancers. The purpose of the present review article is to update the current developments in hydroxamic acid hybrids with an emphasis on anticancer activity, structure-activity relationships, and mechanisms of action.
Identifiants
pubmed: 32791404
pii: S0223-5234(20)30651-6
doi: 10.1016/j.ejmech.2020.112679
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Hydroxamic Acids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
112679Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.